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Kidney diseases manifest in progressive loss of renal
function, which ultimately leads to complete kidney failure.
The mechanisms underlying the origins and progression of
kidney diseases are not fully understood. Multiple factors
involved in the pathogenesis of kidney diseases have made
the traditional candidate gene approach of limited value
toward full understanding of the molecular mechanisms of
these diseases. A systems biology approach that integrates
computational modeling with large-scale data gathering of
the molecular changes could be useful in identifying the
multiple interacting genes and their products that drive
kidney diseases. Advances in biotechnology now make it
possible to gather large data sets to characterize the role of
the genome, epigenome, transcriptome, proteome, and
metabolome in kidney diseases. When combined with
computational analyses, these experimental approaches will
provide a comprehensive understanding of the underlying
biological processes. Multiscale analysis that connects the
molecular interactions and cell biology of different kidney
cells to renal physiology and pathology can be utilized to
identify modules of biological and clinical importance that
are perturbed in disease processes. This integration of
experimental approaches and computational modeling is
expected to generate new knowledge that can help to
identify marker sets to guide the diagnosis, monitor disease
progression, and identify new therapeutic targets.
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Most kidney diseases have complex pathogenesis involving
the interplay of genetic and environmental factors. Diag-
nostic and treatment decisions are typically based on kidney
histology, a limited set of serologic markers, and clinical
manifestations of the disease. Currently, we do not have
sufficiently sensitive or specific tests to detect early disease,
predict disease progression, or monitor treatment response.
Previous studies have identified many candidate genes
involved in the pathogenesis of kidney diseases. Although
many of these genes have important roles in disease
progression and pathophysiology, they do not independently
serve as reliable indicators of the clinical disease state and
progression rate. Many important questions regarding kidney
diseases remain unanswered: What are the temporal and
causal relationships between glomerular and tubular injuries?
What are the interactions and temporal relationships among
podocyte, mesangial, and endothelial cell injuries? Why
proteinuria does not always correlate with the decline of
kidney function? What are the drivers of kidney disease
progression? To address these complex questions, it is critical
to understand the regulatory networks that underlie the
functions of and interactions between various types of cells
within the kidney. Such an understanding is best obtained
from studying the regulatory networks within and between
cells. Systems biology allows us to analyze these regulatory
networks in a temporal and spatial manner. Detailed
characterization of kidney diseases at the systems level could
yield the needed integrative knowledge to better understand
the molecular relationships underlying the pathogenesis of
different types of kidney diseases, to develop more reliable
biomarker sets for diagnosis and treatment, and to
personalize the care of individual patients.
With the advent of next-generation sequencing technol-
ogies and methods to identify molecular species and
interactions at the genome-wide scale, it is theoretically
feasible to generate a global picture of cellular functions in
the kidney from a molecular perspective and to link
phenotype to the molecular networks that govern pathophys-
iological changes. This approach presents an opportunity to
identify the key pathways and genes operative in disease and
health and to characterize mechanistic details that contribute
to the phenotype of the disease. In addition, the ability to
collect genomic data on individual patients in a more
affordable and expeditious manner allows us to better
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elucidate the role of genomic variation in disease manifesta-
tion under varying environmental conditions.
The field of systems biology has grown in the past decade
because of the development of new experimental and
computational tools that enable us to connect gene–cell–
organ regulatory mechanisms at multiple scales and integrate
findings from molecular and cell biology with kidney
structure and function. Here, we provide an overview of
systems biology approaches applied to the study of kidney
diseases. We focus on the rationale rather than the detailed
methodology of these approaches and provide salient
examples in which systems biology approaches have ad-
vanced our understanding of kidney diseases. Limitations of
current applications of systems biology in kidney disease are
also discussed. Through this review, we hope that both
clinicians and researchers could better understand the
rationale and appreciate the potential of systems biology
approaches, and that researchers could gain additional
knowledge on the advantages, limitations, and applications
of systems biology approaches in the study of kidney diseases.
EXPERIMENTAL APPROACHES
A unique identifiable characteristic of experimental ap-
proaches used in systems biology is the capacity to measure
multiple entities simultaneously. Genomics, transcriptomics,
proteomics, metabolomics, and other genome-wide-scale
experimental methods referred to as ‘omics’ technologies
are capable of measuring changes in a large number of
components and interactions to provide an overview of
different conditions: healthy versus diseased state, before
versus after drug treatment, and one cell type versus another.
Data from these experiments are analyzed to identify groups
of components and patterns of interactions that change upon
perturbation. Databases that integrate and organize data
from such omics-type profiling experiments, focused on the
kidney, are available. The different regulatory layers of data
can be classified as genomics, epigenomics, DNA/transcrip-
tion factor regulomics, transcriptomics, proteomics, ki-
nomics, and metabolomics (summarized in Figure 1).
Specific examples of omic-level analysis related to the kidney
are presented in Table 1. Major advantages and limitations of
omic approaches are summarized in Table 2. Online
repositories and catalogs of omic-level data sets and studies
are listed in Table 3.
Genome-wide profiling of kidney diseases
Great progress in genome-wide mapping of complex traits in
humans was made by genome-wide association (GWA)
studies and the admixture linkage analyses. A GWA study
correlates allele frequencies in an unbiased manner at each of
several hundred thousand markers spaced throughout the
genome with trait variation in a population-based sample.1
In contrast, admixture mapping relies on the presence of
extended haplotypes from parental ancestry to map a trait or
disease that is more prevalent in one ethnic population than
another. These approaches have been used to characterize
chronic kidney disease,2 diabetic nephropathy,3,4 immuno-
globulin A nephropathy,5 and focal segmental glomerulo-
sclerosis (FSGS).6–8 For a detailed discussion about study
design and execution of GWA analysis, readers are referred to
Sale et al.9 and Iles.10
Most GWA studies have shown that disease traits are
associated with small to moderate effects at several loci, and
only a few loci with large effects have been identified.
Similarly, when investigators from the Family Investigation of
Nephropathy and Diabetes study used glomerular filtration
rate as a quantitative trait to detect susceptibility loci for
diabetic nephropathy in patients from different ethnic
populations by admixture linkage analysis, they found that
multiple loci of small effects were linked to glomerular
filtration rate but none had large effects.4 Other studies that
use admixture scan in end-stage renal disease patients of
African ancestry have found that the MYH9 gene is highly
associated with FSGS and human immunodeficiency virus-
associated nephropathy.6,7 More recently, Genovese et al.11
examined the risk alleles linked to FSGS in a large cohort of
African Americans, using the GWA approach, and identified
strong association of FSGS with two alleles of the ApoL1 gene,
which is located on the same region of chromosome 22 as
MYH9. In fact, the statistical significance of the two ApoL1
variants was 35 orders of magnitude stronger than that for
the MYH9 single-nucleotide polymorphisms. When the
effects of ApoL1 variants were excluded, no residual
association remained after correction for multiple single-
nucleotide polymorphism testing.11
For most complex traits identified in humans, the sum of
genetic effects comprises less than half of the total trait
heritability. The remaining effects are thought to be due to
untested rare variants, gene–gene, and gene–environment
interactions. To improve the quality of GWA studies, the
candidate locus could be re-sequenced in large cohorts, and
eventually whole-genome sequencing of large numbers of
subjects would be needed. An alternative approach is to
integrate the functional biological knowledge with gene
association analyses at a systems level. Systems genetics can
be used to integrate large sets of genetic variants and/or genes
with other functional data sets, such as protein–protein
interactions and cell-signaling pathways, to further charac-
terize the biology of the complex traits.12 The approach of
identifying genomic loci, where genetic variants significantly
affect gene expression patterns, is called expression quanti-
tative trait locus (eQTL) mapping. Papeta et al.13 have used
the eQTL approach to understand the mechanisms of kidney
disease. They performed eQTL analysis of podocytes in
HIV-1 transgenic mice to gain insight into the genetic
susceptibility of human immunodeficiency virus-associated
nephropathy.13 They found that transcript levels of the
podocyte gene nephrosis 2 homolog (Nphs2) were heritable
and controlled by an ancestral eQTL. In addition, Nphs2
expression was controlled by two eQTLs that localized to the
nephropathy susceptibility intervals in the genome loci of
their origin. These data demonstrate that transcript levels of
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Nphs2 and related genes expressed in the podocytes are
networked, and suggest that the genetic lesions introduced by
human immunodeficiency virus-associated nephropathy
susceptibility alleles perturb this regulatory network and
transcriptional responses to HIV-1.
With the development of second-generation sequencing
technology that enables massively parallel sequencing, it is
now possible for individual laboratories to sequence the
whole human genome. Although technically feasible, the cost
and capacity to sequence the whole human genome of
many individuals is still prohibitive for most laboratories.
Although complete sequencing of the genome has the ability
to discover the complete spectrum of genomic changes
including base substitutions, rearrangements, and copy
number, less comprehensive approaches with incomplete
coverage—such as whole or partial exome and transcriptome
sequencing—can provide the same depth of coverage in less
time and reduced cost.14 Targeted sequencing approaches,
such as whole or partial exome and transcriptome sequenc-
ing, can be applied to diseases in which the causative genes
have been identified, or if the mutation is known to occur in
the exome. Investigators can apply specific capture methods
to select for the desired genomic region before massively
parallel sequencing. As the human exome comprises
approximately 1% of the genome, significant greater
sequence coverage can be achieved with a lower cost than
whole-genome sequencing. Whole-exome sequencing has not
been applied to the study of kidney disease, but has been used
successfully in identifying a novel coding variant as a result of
a missense substitution in a gene, SLC26A3, known to cause
congenital chloride-losing diarrhea15 and variants in the
DHODH gene that causes Miller syndrome.16
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Figure 1 | ‘Omic’ approaches to profile cellular processes. Both external stimuli and internal signals can initiate the activation of
downstream signaling pathways through post-transcriptional modification of signaling molecules, such as protein kinases, by
phosphorylation. Activation of the signaling cascade leads to either transcriptional activation by recruitment and assembly of the
transcriptional complex on the DNA, transcription factor/DNA (TF/DNA) interaction, or inhibition of transcriptional activation by exclusion of
key TFs from the complex. Covalent modifications of the DNA by methylation and of histones by acetylation have a major role in the
regulation of gene expression. Variations in the coding region of the genome result in mutations of the gene transcripts, and changes in
non-coding region could affect the regulation of gene expression. Gene transcripts as messenger RNAs in the cytoplasm are translated into
proteins. The protein products synthesized in response to the initial signal serve to maintain cellular integrity and react to perturbations in
the systems by initiating additional signals or catalyze reactions that generate specific metabolites as a by-product. Characterization of
these processes at the systems level is known as the ‘omics’ approaches: kinome for phosphorylation of proteins, TF/DNA regulome for
regulation of transcription by the interaction of TF with DNA, epigenome for modification of histones and DNA, genome for the sequence of
DNA, transcriptome for the mRNA transcripts of the expressed genes, proteome for the protein composition, and metabolome for the
metabolites that are generated in a specific tissue or cell (Red P¼phosphorylation, Me¼methylation, Ac¼ acetylation, line with poly A
tail¼mRNA). miRNA, microRNA.
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Table 1 | Specific examples of omic-level analysis in nephrology
Omic
approaches Methods Reference Brief description of the results
Disease/biological
process
Animal and/or
human
Genomic GWAS and
admixture
linkage-based
approaches
Kottgen et al.2 Identified genetic susceptibility loci for GFR and CKD
by GWAS in population cohorts.
CKD Human
Pezzolesi et al.3 Identified two susceptibility loci for the development
of DN in a cohort of patient with type 1 diabetes
using a GWA scan.
DN Human
Schelling et al.4 Discovered multiple chromosomal regions that are
linked to GFR as a quantitative trait by admixture
linkage analysis in diabetic sibpairs from different
ethnic backgrounds recruited for the Family
Investigation of Nephropathy and Diabetes study.
DN Human
Feehally et al.5 Identified a region of the MHC locus to be associated
with IgA nephropathy using both family-based
association and case-based analyses.
IgA Human
Kao et al.6 A region of chromosome 22q12, which includes
MYH9, is associated with excess African ancestry and
nondiabetic ESRD by admixture mapping. Several
SNPs in MYH9 accounts for a large percentage of the
risk for ESRD observed in African Americans.
CKD in African
American
Human
Kopp et al.7 Identified a strong linkage disequilibrium that
centered on MYH9 in a region of ch22 using an
admixture-mapping genome scan on African
Americans with FSGS and controls.
CKD in African
American
Human
Genovese et al.8 Identified genetic variants in the region of ch22
containing part of the MYH9 and APOL1 genes
associated with increased risk of FSGS in African
Americans, but not in European Americans.
CKD in African
American
Human
Papeta et al.13 eQTL analysis of podocyte genes in a murine model
of HIVAN revealed that HIV-1 transgene expression
interferes with the expression of a podocyte-specific
gene, Nphs2, which is controlled by other loci in the
genome that had been previously shown to confer
susceptibility to the development of HIVAN in mice.
HIVAN Animal
Transcriptomic Expression
profiling by
microarray
Baelde et al.117 Identified 615 differentially expressed mRNAs that
are involved in cytoskeleton formation and tissue
injury repair machinery by comparing the gene
expression profile of glomerular RNA isolated from
two patients with DN and two normal patients.
DN Human
Berthier et al.18 Gene expression profiling was performed on kidney
biopsy samples from control subjects and early and
progressive type 2 DN, as well as kidney samples
from two murine models of diabetic nephropathy.
Janus kinase–signal transducer and activator of
transcription pathway was highly regulated in the
glomeruli and tubulointerstitial samples from human
with DN, but not murine models of DN.
DN Human, animal
Moczulski
et al.118
mRNA expression profiles of peripheral blood
mononuclear cells from type I diabetic patients with
and without DN were determined. The expression of
198 candidate genes suggested to be involved in DN
from previous publications was analyzed.
Thrombospondin 1 and cyclooxygenase were
overexpressed, but matrix metalloproteinase 9 and
cyclooxygenase 2 genes were underexpressed in
patients with DN.
DN Human
Hodgin et al.19 Glomeruli mRNA from formalin-fixed and paraffin-
embedded biopsy samples of 21 patients with
biopsy-proven MCD, FSGS, or collapsing variant of
FSGS and normal renal biopsies were profiled by
microarray. Class comparison analysis of FSGS +
collapsing FSGS combined versus normal + MCD
revealed 316 differentially regulated genes, including
podocyte slit diaphragm genes. Genes involved in
development, differentiation, and morphogenesis,
cell motility and migration, cytoskeleton
organization, and signal transduction are
overrepresented in this list of differentially regulated
genes.
Glomerular
diseases (MCD,
FSGS, collapsing
FSGS)
Human
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Table 1 | Continued
Omic
approaches Methods Reference Brief description of the results
Disease/biological
process
Animal and/or
human
Peterson et al.20 Microarray analysis of isolated glomeruli from
patients with proliferative lupus GN revealed
significant heterogeneity in transcript expression
between samples. Four gene clusters from the
expression profiling identified the presence of B cells,
several myelomonocytic lineages, fibroblast and
epithelial cell proliferation, matrix alterations, and
expression of type I IFN-inducible genes.
Proliferative lupus
GN
Human
Ju et al.21 Expression profiling on kidneys of TGF-b 1 transgenic
(Tg) mice identified 43 genes that were able to
discriminate kidneys based on the severity of
glomerular cell apoptosis. Expression profiles of
human orthologs of these 43 genes in human kidney
biopsies were significantly related to the kidney
function. Protein expression patterns of selected
genes were validated by immunohistochemistry in
Tg mice and patients with IgA nephropathy and CKD.
TGF-b 1 transgenic
model of CKD, IgA
Animal, human
Bhavnani et al.22 Expression profiles of microdissected renal tubules
from kidney biopsy of 106 patients with renal disease
were determined. Network visualization and topology
analysis were applied to the expression profiles of each
renal disease to determine the relationship between
disease, genes, and regulation of genes. Results
suggest that many genes associated with a single
disease and fewer genes associated with many
diseases. There are unexpected combinations of renal
diseases that share relatively large numbers of genes.
For instance, FSGS, which is believed to be
predominantly a non-inflammatory process, shares
more genes with SLE, which is a predominantly an
inflammatory process, than with another non-
inflammatory disease such as membranous
glomerulopathy.
IgAN, SLE, FSGS,
MGN, MCD, TMD,
DN
Human
Teramoto et al.24 Gene expression analysis of microdissected glomeruli
from a murine model of SLE revealed upregulation of
genes encoding for complement proteins, adhesion
molecules, chemokines and receptors, and antigen-
presenting machinery. Genes involved in Th1 response
and induced by interferon-gamma were observed.
SLE Animal
Susztak et al.23 Microarray and phenotype analysis were performed
on two murine models of DN. Weighted vote-based
supervised analytical methods were used to identify
genes whose expression can classify samples based
on the presence or absence of mesangial matrix
expansion. Hydroxysteroid dehydrogenase-3b isotype 4
and osteopontin were lead classifier genes.
DN Animal
Schmid et al.30 mRNA expression screening of the tubulointerstitial
compartments of human renal biopsies combined
with hypothesis-driven pathway analysis were used
to evaluate pathogenic factors implicated in DN. A
specific NF-kB promoter module was identified in the
promoter regions of regulated NF-kB targets.
DN Human
Wiggins et al.25 Gene expression patterns of aging in the rat
glomeruli resembled atherosclerosis. Authors
identified and confirmed NF-kB as a likely
transcriptional regulator of these events.
Aging Animal
Godwin et al.37 Global miRNA expression analysis was performed on
kidneys of mice that underwent unilateral warm
ischemia. Nine differentially expressed miRNAs were
identified.
Renal ischemia
reperfusion injury
Animal
Epigenomic Kikuchi et al.33 To determine DNA methylation-dependent
regulation of gene silencing as the mechanism of
differential expression of organic anion transporters
in the liver and kidney, the authors profiled the
region near the transcription start sites of mouse
solute carrier transporters for tissue-dependent
differentially methylated regions. A role of DNA
Differential
expression of
organic anion
transporters in the
liver and kidney
Animal
Table 1 continued on following page
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Transcriptomics and protein–DNA regulomics of kidney
diseases
Transcriptomics is defined as the analysis of mRNA
expression patterns at the genome-wide scale. Such experi-
ments have been the most widely applied systems-level
approach so far. Changes in the mRNA levels are measured
by microarray technology, which is being replaced by high-
throughput sequencing of mRNAs, also known as RNA-seq.
Efforts to combine transcriptomic data from biological
samples annotated with clinical parameters have been made
to generate a broad and unbiased view of disease processes
and to identify transcriptomic fingerprints associated with
defined clinical outcomes. Transcriptomic studies have been
conducted to profile expression changes in diabetic nephro-
pathy (DN),17,18 FSGS,19 lupus nephritis,20 chronic kidney
disease,21 and glomerular diseases,22 as well as in animal
models of DN,23 chronic kidney disease,21 lupus nephritis,24
and aging.25 Transcriptomic data sets have provided insights
into the mechanisms of disease processes and identified novel
genes responsible for the progression of kidney diseases.
Transcriptomic analysis has the potential to define the
molecular patterns of disease, allowing early diagnosis,
prediction of prognosis, and response to therapy. The current
use of transcriptomics in kidney disease research has several
limitations. The heterogeneity of kidney tissue (different cell
types), as well as the genomic variability of human samples,
makes the interpretation of transcriptomic data challenging.
Although attempts have been made to differentiate the
compartmental gene expression in the glomerulus and
tubulointerstitium by microdissection or laser capture, each
Table 1 | Continued
Omic
approaches Methods Reference Brief description of the results
Disease/biological
process
Animal and/or
human
methylation in the kidney-specific expression of
amino acid transporters was identified.
Bechtel et al.34 Genome-wide methylation screen was performed on
fibroblasts isolated from fibrotic and nonfibrotic
kidneys. RASAL1, encoding an inhibitor of the Ras
oncoprotein, is hypermethylated in fibroblasts from
fibrotic kidneys. Hypermethylation of RASAL1 is
associated with the perpetuation of fibroblast
activation and fibrogenesis in the kidney.
Kidney
fibrogenesis
Human, animal
Proteomic DIGE Sharma et al.119 DIGE was used to study the urine of three DN
patients. Alpha 1 antitrypsin (AAT) was found to be
higher in the urine of diabetic patients.
Immunostaining for AAT is increased in fibrotic
regions of the kidneys.
DN Human
Rao et al.120 DIGE-based analysis of urine from controls and type 2
diabetic patients with normoalbuminuria,
microalbuminuria, and macroalbuminuria identified
62 unique proteins. Eleven proteins were
differentially regulated with progressive albuminuria.
DN Human
Mass
spectroscopy
Mischak et al.121 Urinary polypeptide patterns from normal and type 2
diabetic patients were compared by capillary
electrophoresis–mass spectrometry. A specific
polypeptide pattern was observed in patients with
albumin excretion rate 4100mg albumin/l and to a
lesser degree in patients with lower rates of albumin
excretion.
DN Human
Kim et al.122 2D gel electrophoresis was used to identify serum
protein markers that can predict the progressive
nephropathy in type 2 diabetic patients (normo- and
microalbuminuria, and those with chronic renal
failure). Serum proteins were further selected and
identified by ESI-Q-TOF mass spectrometry. Serum
extracellular glutathione peroxidase and
apolipoprotein E were identified as potential serum
biomarkers for the diagnosis of type 2 diabetics with
nephropathy.
DN Human
Meier et al.123 High-resolution capillary electrophoresis coupled to
mass spectrometry was used to investigate urinary
polypeptides and proteins from type 1 diabetic
patient. Clusters of polypeptides were identified in
diabetic patients. Specific polypeptide patterns
characteristic for healthy controls and diabetic
patients and subdivision of patients were observed.
DN Human
Abbreviations: CKD, chronic kidney disease; DIGE, differential in gel electrophoresis; DN, diabetic nephropathy; ESRD, end-stage renal disease; eQTL, expression quantitative
trait locus; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate; GN, glomerulonephritis; GWAS, genome-wide association study; HIVAN, HIV-1-associated
nephropathy; IgA, immunoglobulin A; IgAN, immunoglobulin A nephritis; IFN, interferon; MCD, minimal change disease; MGN, membranous glomerulonephritis; MHC, major
histocompatibility complex; miRNA, micro ribonucleic acid; mRNA, messenger ribonucleic acid; NF-kB, nuclear factor kappa B; SLE, systemic lupus erythematosus; SNP, single-
nucleotide polymorphism; TGF-b 1, transforming growth factor beta 1; TMD, thin basement membrane disease.
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of these compartments comprised several cell types—
endothelial cells, podocytes, and mesangial cells in the
glomerulus and tubular epithelial cells, endothelial cells,
and infiltrating cells from the circulation in the tubulointer-
stitium—and the gene expression profile of the different cell
types in the compartments could be variable and not able to
be distinguished from each other even with microdissection.
In addition, changes in mRNA levels do not always reflect
changes in the protein level or protein function due to
multiple layers of regulation occurring from transcription to
protein synthesis and post-translational modifications
needed for understanding regulatory mechanisms.
Quantitative changes in mRNA levels do not directly
explain how regulatory mechanisms are altered during
disease to induce changes in gene expression, and in turn
lead to changes in cellular- and tissue-level phenotypes.
Genome-wide measurements of protein–DNA interactions by
chromatin immunoprecipitation (ChIP) combined with
quantitative measurements of transcriptomes are increasingly
used to connect regulatory inputs with transcriptional
Table 2 | Advantages and limitations of systems biology approaches
Advantages Limitations
Genomics Potential for early detection and risk prediction of disease
Provide the molecular basis for rational drug design
Understand why different individuals respond differently to
the same drugs and allow prediction of response to therapy
(pharmacogenomics).
Large sample size and cost required for genomic studies
Extreme multiple testing with predisposition of false
positives
Relatively low coverage of the genotyping platforms,
particularly in regions with high levels of genetic
heterogeneity
For most complex traits identified in humans, the sum of
genetic effects comprises less than half of the total trait
heritability.
Epigenomics (DNA
methylation, histone
modification)
Provide information on the regulation of gene expression
that cannot be captured by gene expression profiles
Potential for earlier disease detection as methylation
changes occurs early and frequently in certain biological
processes (i.e., tumorigenesis)
Epigenomic profiles are relatively stable and resistant to
changes in physiological state or sample-collection changes.
The ‘histone code’ is not fully deciphered
Relatively large amount of specimen (DNA, chromatin) is
required
Several different assays may be required to study different
types of epigenetic changes (DNA methylation, histone
acetylation, and methylation)
Cell and tissue specificity of epigenetic modifications would
require sample collection from the diseased organ
Difficulties with determining a reference cell epigenomic
state as epigenetic modifications are variable across cell
type, differentiation state, hormonal, and environmental
conditions.
Transcriptomics
(mRNA and miRNA)
More affordable compared with other omics assays
Standardized experimental methodology
Availability of tissue- and disease-specific data sets for
comparison
Microarrays provide comprehensive coverage of the cellular
transcriptomic repertoire.
mRNA transcript level does not necessarily correspond to
protein level or activity
Analytical tools to extrapolate expression to upstream
signaling pathway activation are not standardized nor
reliable
Incomplete knowledge of gene targets regulated by a given
miRNA and computational prediction of miRNAs targets are
not exact.
Protein-DNA
regulomics
Provides information on the regulation of gene expression
by DNA binding proteins (including transcription factors) and
upstream signaling pathways
Allows true genome-wide discovery of protein bindings sites
on DNA without comprehensive previous knowledge of
genomic sequences
Relatively low sample input amount required (50 ng of
fragmented, ChIP-enriched DNA).
ChIP is not a functional assay therefore does not provide
functional significance (e.g., enrichment of DNA fragments
that are located near a protein does not necessarily reflect
either activation or repression of transcription of the
associated gene)
Immunoprecipitation-based assay is heavily dependent on
the availability and quality of specific antibodies
ChIP assay often provides low signals in comparison with
negative controls, which can lead to false negative or
inconclusive results (e.g., low signal/noise ratio).
Proteomics (urine
proteome and kidney
proteome)
Urine proteins are relatively stable
Non-invasive, repeat sampling of urine is feasible
Urine contains fewer proteins than serum
Potentially more reflective of phenotype.
Quality and quantity of urine proteins are affected by diet
and exercise
Higher amount of urine protein in disease could bias results
(e.g., nephrotic range proteinuria)
Proteomic analysis of kidney tissue might not be possible
using percutaneous biopsy samples due to limitation in
sample quantity
Sample storage, preparation and analysis could affect results
Low-abundance proteins are not well characterized with
available methods.
Metabolomics Potentially more reflective of the phenotype. Not yet validated in kidney disease.
Abbreviations: ChIP, chromatin immunoprecipitation; miRNA, microRNA; mRNA, messenger RNA.
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outputs. Although genome-wide screening of binding sites by
DNA binding proteins with ChIP had mostly relied on DNA
microarray technology in the past, ChIP followed by high-
throughput sequencing (ChIP-seq), which offers distinct
advantages in increased specificity, sensitivity, and genome-
wide comprehensiveness, is now being used more widely.26
The key challenge for ChIP-seq algorithms is to identify
reproducibly true binding locations while including as few
Table 3 | Online resources
Omics repositories: National Human Genome Research Institute, Office of
Population Genomics (http://www.genome.gov/gwastudies/)
A catalog of GWAS publications to date. This includes GWAS
on kidney diseases.
Nephromine (http://www.nephromine.org) A web-based platform for integrative data mining of gene
expression data sets specifically for renal diseases.
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo)
A collection of gene expression experiments across many
platforms.
ArrayExpress Archive and Gene Expression Atlas
(http://www.ebi.ac.uk/arrayexpress)
A database of functional genomics experiments including
gene expression. A small subset of the database can be
queried for gene expression under different biological
conditions.
Stanford Microarray Database (http://smd.stanford.edu/
index.shtml)
A resource for storage, annotation, visualization, and sharing
of microarray data generated from various model organisms,
experimental conditions in different microarray platforms.
The database contains microarray analysis of human kidney.
Human Kidney and Urine Proteome Project
(http://www.hkupp.org)
Databases of proteomic data generated from normal human
kidney glomerulus and urine.
Human glomerular SAGE transcriptome database
(http://cgap.nci.nih.gov/SAGE)
SAGE library constructed using glomeruli isolated from the
unaffected pole of a kidney of a male patient surgically
removed for renal cell carcinoma.
Data preprocessing: Bioconductor (http://www.bioconductor.org/) Tools for the pre-processing, quality assessment, and analysis
of omic data including microarrays and sequence data sets.
dChip (https://sites.google.com/site/dchipsoft/) Software for the analysis and visualization of gene expression
and SNP microarrays.
Functional
annotation:
Database for Annotation, Visualization, and Integrated
Discovery (http://david.abcc.ncifcrf.gov/)
A set of tools that allow users to derive biological meaning
from a list of genes.
GoMiner (http://discover.nci.nih.gov/gominer/index.jsp) A tool that takes lists of genes generated from omic analysis
and uses GO to identify biological processes, functions, and
components represented in these lists.
Protein ANalysis THrough Evolutionary Relationships
(http://www.pantherdb.org/)
A classification system where genes are classified by their
functions based on published data and evolutionary
relationships to predict function.
Pathway and
interaction network
analysis
Biogrid (http://thebiogrid.org/) An online repository of protein and genetic interactions
based on publications.
Pathway Commons—Human Protein Reference Database
(http://www.hprd.org/)
A platform for visualization and integration information
pertaining to domain architecture, post-translational
modifications, interaction networks, and disease association
for each protein in the human proteome.
Pathway Interaction Database (http://pid.nci.nih.gov/) A curated collection of information about known
biomolecular interactions and key cellular processes
assembled into signaling pathways.
Kyoto Encyclopedia of Genes and Genomes
(http://www.genome.jp/kegg/)
An integrated database resource consisting of 16 main
databases that are broadly categorized into systems
information, genomic information, and chemical information.
It is widely used as a reference knowledge base for biological
interpretation of large-scale data sets.
STRING (http://string-db.org/) A database of known and predicted protein interactions.
FunCoup (http://funcoup.sbc.su.se/) A statistical framework of data integration for finding
function coupling between proteins. It contains a whole
predicted interactome for eight organisms.
Gene Set Enrichment Analysis
(http://www.broadinstitute.org/gsea/index.jsp)
A computational method that determines whether an a
priori defined set of genes shows statistically significant,
concordant differences between two biological states.
Lists2Networks (http://amp.pharm.mssm.edu/lachmann/
upload/register.php)
A web-based system that allows user to upload lists of
mammalian genes/proteins into a server-based program for
analysis. The system allows user to expand lists using existing
mammalian networks of protein–protein interactions, co-
expression correlation, as well as to apply gene-list
enrichment analyses against many gene-list libraries.
Abbreviations: GO, gene ontology; GWAS, genome-wide association study; SAGE, serial analysis of gene expression; SNP, single-nucleotide polymorphism.
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false positives as possible.27 The main advantage of ChIP-seq
experiments is that identified binding sites for transcription
factors can be directly correlated with transcriptional
changes, connecting gene expression to the first layer of
regulation. Transcriptional regulatory networks upstream of
gene expression can be deduced by combining in silico
promoter motif-based analyses combined with enrichment
analysis of integrated results from ChIP-chip or ChIP
experiments.28 This approach has been recently described
by Ma’ayan and He.29
It is important to understand how the transcriptional
regulatory networks are altered in kidney diseases. The
transcription regulatory networks involved in the pathogen-
esis of DN were studied in a cohort of patients with
progressive DN.30 By comparing the gene expression profiles
in the tubulointerstitial compartment of patients with DN
with those with mild disease, it was revealed that inflamma-
tion-stress response genes such as nuclear factor kappa B
(NF-kB) target genes are differentially expressed. Systematic
promoter module analysis of the upregulated NF-kB-
dependent genes identified an enrichment of a specific
NF-kB-binding module in the promoter regions of known
NF-kB targets that were upregulated in the patients with
progressive DN, but not in patients with mild disease or the
controls.30 Using this specific NF-kB module, they were able
to correctly predict other genes that are upregulated in the
patients with progressive DN.
Epigenetics profiling of kidney diseases
The term epigenetics broadly refers to regulatory mechan-
isms that arise due to differences in the state of chromatin
and the proteins associated with it. Such differences arise
because of covalent modifications such as histone acetylation
or DNA methylation. These modifications are thought to
alter chromatin density and accessibility of the transcrip-
tional machinery to the DNA, thereby modulating the
expression of genes. Epigenetic regulation has a crucial role
in normal physiological development, as well as in patholog-
ical conditions. Epigenetics of kidney development has been
reviewed previously.31,32 DNA methylation on epigenetic
signatures of kidney-specific transporters was examined by
Yagi et al.33 They demonstrated a central role for DNA
methylation in kidney-specific expression of amino acid
transporters.33 Bechtel et al.34 compared primary human
fibroblasts from fibrotic kidneys with fibroblasts from non-
fibrotic kidneys using a genome-wide methylation screen.
This screen revealed 12 genes that were methylated in all
seven tested fibrotic fibroblast samples and non-methylated
in all tested non-fibrotic fibroblast samples. They identified
RASAL1 as a candidate that may facilitate fibroblast
activation and progression of renal fibrosis. These two
studies demonstrate that environmental conditions influence
the epigenetic state of a cell. Epigenetics provide an added
layer of regulation that could mediate the relationship
between genotype and environmental factors. Therefore,
characterization of the epigenomic profile of kidney disease
could help us understand the disease pathogenesis, as well as
identify potential new biomarkers for disease diagnosis.
Integration of DNA methylation profile with gene expression
profile could give us a better understanding of gene
regulation in kidney disease.
MicroRNA profiling to study kidney disease
MicroRNAs (miRNAs) are a class of endogenous, small, non-
coding 21- or 22-nt-long RNAs that have been implicated in
the regulation of multiple biological processes. MiRNAs are
critical in the maintenance of glomerular homeostasis and in
the progression of renal disease.35 When Dicer, an enzyme
that converts pre-miRNAs into functional small-interfering
RNAs, was inactivated in mouse podocytes, the mice
developed proteinuria and died subsequently from renal
failure.36 Similarly, interruption of miRNA biogenesis in
mouse podocytes resulted in proteinuria, podocyte dediffer-
entiation, and crescent formation, leading to end-stage
kidney diseases.35 Global miRNA expression profiling on
samples prepared from the kidneys of C57BL/6 mice that
underwent unilateral warm ischemia revealed nine miRNAs
that are differentially expressed following ischemia–reperfu-
sion injury when compared with sham controls.37 One of
these nine miRNAs is miR-21, which may have a role in
protecting renal tubular epithelial cells from death. Recent
studies suggest that miR-192 may also regulate transforming
growth factor-b/Smad3 signaling in the development of renal
fibrosis.38–40
The expression profile of miRNA offers some important
potential advantages over standard mRNA or other protein-
based profiles. MiRNAs appear to be very stable in tissues
and biological fluids, including urine.41 They are protected
from endogenous RNase by virtue of their small size and
perhaps by packaging within exosomes, which protect
miRNAs from RNase degradation.41 In addition, the tissue-
specific nature of miRNA expression makes them potentially
ideal candidates for serving as biomarkers.42 The total
number of human miRNAs, estimated to be between 700
and 1000, is considerably smaller than the number of
protein-coding mRNAs (422,000).43 MiRNAs have been
detected in urine and could be used as biomarkers for kidney
disease.44 These urinary miRNAs may be filtered directly
from the kidney or the urinary tract; alternatively, miRNAs
from detached cells or packaged in exosome may also
contribute to the miRNAs detected in the urine. However,
there are still major challenges to overcome before expression
profiling of miRNAs can be used widely. For instance,
miRNA biology and regulation are still unclear and
bioinformatics prediction of miRNA-target pairs is still
unreliable.
Proteomics profiling to study kidney diseases
The use of proteomics in kidney disease research has grown
substantially over the past decade. The proteomics approach
has been applied to study renal physiology and this has been
reviewed by Hoorn et al.45 Proteomics technologies have
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been used to identify promising new biomarkers for acute
kidney injury and chronic kidney disease. Proteomics may
also help to identify new uremic toxins in renal failure
patients. Proteomic analysis has been performed to profile
normal human and rat renal cortices,46 human renal
glomerulus,47,48 urine,49,50 and urinary exosomes.51 Many
of these studies have tried to identify a single biomarker for
kidney disease. This has not been successful because of the
biological variability and complex pathophysiology of kidney
diseases. Development of classifiers based on sets of protein
biomarkers may be more predictive for kidney disease
progression.
Urinary proteins can originate from the filtering of
plasma, vascular damage and/or leakage, alterations in
tubular metabolism, and the reabsorption or direct shedding
and/or secretion of proteins by cells throughout the
urological tract. Urine represents an attractive source of
potential biomarkers in renal diseases because of the non-
invasive nature, easy collection, and low amount of proteins
and peptides that are required for analysis. Numerous protein
biomarkers have been identified in both health and disease.
Urinary proteomics has been used to identify the early
biomarkers of acute kidney injury.52 Specific protein
panels from urine could help in early diagnosis of acute
kidney injury and assess the severity and duration of the
disease. However, the sensitivity and specificity of these
markers needs to be validated in large clinical studies.53
Proteomic studies have also been conducted to identify
biomarkers to predict the development and progression of
diabetic kidney disease (reviewed in Merchant and Klein54
and Rossing et al.55) and immunoglobulin A nephropathy.56
Proteomics has also been used to study patients with other
glomerular diseases, patients on dialysis, or recipients of
kidney transplant.57,58 The proteomic resources of human
kidney tissue and urine have been reviewed recently by
Yamamoto.59
Proteomics-based approaches have generated large
amount of data in clinical medicine. These data could be
used to discover novel biomarker sets and gain mechanistic
insights of disease origins. However, there are substantial
experimental and computational challenges. Methods used to
concentrate the proteins and remove salts often affect the
yield. Numerous methodological and biological variables can
influence peptide profiles.60 One major issue is the
standardization of procedures for clinical applications. Given
the large numbers and varying abundances of different
proteins in biological samples, no single experimental
approach appears adequate for the reproducible character-
ization of the whole proteome state. The nature, number, and
quality of clinical samples, temperature and length of storage,
and nature of sample receptacle are all critical. The Human
Kidney and Urine Proteome Project have been developing a
standardized protocol for urine collection and storage
(http://www.hkupp.org). Standardization of techniques is
required to obtain more reliable proteomics data to study
kidney disease.
Metabolomics profiling to study kidney disease
Whereas proteomics profiling tracks the global expression of
proteins, metabolomics profiling characterizes and quantifies
metabolites. Only a subset of proteins is responsible for
processing metabolites, and thus the information from
proteomics and metabolomics are complimentary, whereas
the combination of these approaches often provides a better
appreciation of cells’, organs’, or organism’s molecular state.
The advantage of metabolomics is that it could reveal changes
in both phenotype and genotype.61 Computational ap-
proaches that would integrate metabolomics and proteomics
data sets may provide more reliable biomarker sets.
Metabolomics has been used to study kidney diseases for
the last several years, although the data are still quite limited.
Studies of metabolite profile in blood, kidney tissue, and
urine have been used to identify early biomarkers for kidney
disease.62,63 It was reported that changes in urine metabolite
profile such as glucose, amino acids, and fatty acids could be
used as early biomarkers for cisplatin-induced acute kidney
injury.62 Metabolomics is also used to identify biomarkers to
distinguish acute rejection from acute kidney injury in
kidney transplant patients.63 However, the application of
metabolomics in kidney disease is still at an early stage.
Validation of these metabolic biomarkers with respect to
reproducibility, sensitivity, and specificity will need to be
performed. Clinical applications are currently limited because
of technical challenges.
COMPUTATIONAL APPROACHES
Computational systems biology is an evolving field that
encompasses a range of approaches from statistical correla-
tion-based methods to network topology analyses, to
dynamical models of biochemical and physiological func-
tions, to detailed stochastic simulations of few components,
to multiscale dynamical models that describe molecular
networks in space and time and physiological functions of
organs and organisms. The large data sets collected at the
different layers of regulatory interactions require the devel-
opment of databases and modeling algorithms capable of
integrating such data to convert information into knowledge.
Statistical models
Genomic studies, transcriptional profiling, genome-wide
ChIP analyses, miRNAs profiling, proteomics, phosphopro-
teomics, and metabolomics produce high-dimensional data
sets. Commonly, these data sets are analyzed by statistical
methods to cluster genes and proteins based on correlated
expression, and then the clusters are linked to functional
categories.20 Clusters identified based on expression similar-
ity64 are commonly linked to biological themes where sets of
co-regulated or co-expressed genes are linked to prior
biological knowledge to assess enrichment for pathways or
other properties.65,66 Correlated changes in the expression or
activity of molecular components are also linked with the
physiological or pathophysiological effects at the organ and
organism levels. Such analyses serve as the starting point for
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understanding the molecular consequences of the different
experimental conditions or disease states. This type of
analyses produce ranked lists of components that vary with
the underlying pathophysiology. Often it is discovered that
such lists of components share biological themes that can
explain observed outcomes. For example, Gene Ontology
enrichment analysis67 is used to score how components from
observed changes in expression belong to the same
biochemical function or are present in a specific cellular or
extracellular location. However, such analyses do not provide
a full understanding of the mechanisms underlying disease
origins or progression. Lacking in this type of analyses is the
regulatory relationships between components in ranked lists
of differentially expressed genes. However, such relationships
can be deduced statistically using Bayesian approaches68,69 or
by linking list members to networks developed from prior
biological knowledge65,66,70,71 (Table 3 contains a list of tools
and databases for functional annotation and pathway and
interaction network analysis). The next step is to integrate
such networks toward mechanistic understanding. To obtain
such mechanistic understanding, there are two broad
challenges that are currently actively being pursued: how do
we integrate data from different type of profiling experi-
mental approaches at different regulatory levels of cellular
regulation? And how do we combine different classes of
genome-wide experimental data with clinical measurements?
Building and analyzing networks
Lists from omic studies can be used to reconstruct models of
cellular networks. This can be done using statistical methods.
Methods used to develop networks directly from expression
data include methods such as Bayesian networks68,69 or
information theory-based approaches.72 Networks can also
be created using prior knowledge such as protein–protein
interactions or cell signaling networks developed from
biochemistry and cell biology literature.65,66,70,71 In addition,
integrating data from different types of profiling experi-
mental approaches, such as those described above, can be
achieved by anchoring genes within prior knowledge net-
works.73 A similar approach allows the construction of
molecular networks that connect diseases to genes based on
GWA studies, miRNAs to the mRNAs they target,74 protein/
DNA interactions based on ChIP analyses,28 protein–protein
interactions,65,66,70,71 metabolic pathway interactions, virus/
host protein interactions,75 and drug–target interactions76 to
each other to form heterogeneous networks made of different
types of nodes and different types of links (Figure 2). Such
networks can be analyzed using clustering algorithms to
identify modules altered in various kidney diseases. Such
modules can serve as sets of disease biomarkers, and
components of the modules can become potential drug
targets. Network analysis algorithms can be used to identify
such modules robustly (see review by Ma’ayan77). Once such
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Figure 2 |Construction of molecular networks. Networks that integrate binary interactions from heterogeneous sources, such as
microRNAs (miRNAs) targeting mRNAs (from databases such as TargetScan or through experiments such as Argonaute HITS-CLIP124 (black
diamond heads), protein/DNA interactions based on ChIP followed by high-throughput sequencing (ChIP-seq) analyses (cyan arrows),
protein–protein interactions (orange links)125, virus/host protein interactions from databases such as VirusMINT75 (gray lines),
kinase–substrate interactions126 (green arrows), and drug–target interactions76 (red diamond heads) from databases such as the
DrugBank127, can be used to build networks made of different types of nodes and links. An example of such network for key components
that have a role in human immunodeficiency virus-associated nephropathy (HIVAN) is given on the right. Dasatinib is an Src inhibitor used
for the treatment of oncologic disorder, but could be tested for its therapeutic potential in the treatment of HIV-associated nephropathy.
Arrowheads indicate activations and diamond heads denote inhibition. NPHS1, nephrosis 1 homolog.
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modules are identified, quantitative dynamical modeling
approaches can be applied to further understand the
dynamical behavior of such modules, and how the dynamics
are altered during pathophysiology.
Dynamical models of renal physiology
The major functions of the kidney include clearance of toxins
and maintenance of fluids, electrolytes, and acid–base
balance. Normal kidney function is maintained by coordi-
nated regulation at different levels of organization (Figure 3).
At the organ level, the heart perfuses the kidney, which is
regulated by the neuro–hormonal system. At the nephron (a
single functional unit of the kidney) level, autoregulation of
renal blood flow, tubuloglomerular feedback loop, and
nephro–vascular exchanges in the medulla are all required
to maintain normal nephron function. At the cellular level,
normal structure and function of endothelium/glomerular
basement membrane/podocyte are essential for the main-
tenance of the glomerular filtration barrier, and polarized
tubular epithelial cells are required for reabsorption and
secretion of fluid and electrolytes along the nephron.
There are several types of computational models of kidney
physiology with varying level of organization: multiorgan
models, models of kidney function at the organ level, models
of the tissue compartments within the kidney, and models of
kidney cell types. The SAPHIR (a Systems Approach for
Physiological Integration of Renal, Cardiac, and Respiratory
function) is the best example of a multiorgan model.78 This is
a model of body fluid homeostasis and blood pressure
regulation and has been reviewed by Thomas.79 Karaaslan
et al.80 developed an integrated cardiovascular/renal model
with emphasis on the role of renal sympathetic nerve activity.
In the 1960s, Guyton et al.81 were the first to develop a global
model of kidney function and the overall regulation of blood
pressure. Ikeda et al.82 extended the Guyton model to the
regulation of acid–base balance. The classical models from
Guyton and Ikeda constitute the basis for current develop-
ment of a core model for fluid and solute regulation. Several
whole kidney models have been also developed to study the
genesis of the medullary osmotic gradient.83,84
Many computational models have been developed to
study different aspects of the local renal physiology, including
membrane and epithelial transport of fluid and electrolytes
for different segments of the nephron,85 autoregulation of
renal blood flow,86,87 and tubuloglomerular feedback.88 At
the glomerular level, many modeling studies analyze factors
involved in single-nephron glomerular filtration rate89 and
structural defect for reduced glomerular filtration capacity.90
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Figure 3 |Multiscale analysis of kidney function. Maintenance of renal function requires the coordinated regulation from other organ
systems (neuroendocrine and cardiovascular) and various tissue compartments and cells within the kidney. To recapitulate normal renal
physiology in biological models, this multiscale organization from organ systems down to cell/gene level will need to be determined. The
interactions at several levels have been described: Systems Approach for Physiological Integration of Renal, Cardiac, and Respiratory
(SAPHIR) models, as well as models of autoregulation of glomerular blood flow, tubuloglomerular feedback, and tubulovascular exchange.
Clinical parameters that we can use to assess and infer the function of organ systems and organs include blood pressure and cardiac
function for cardiovascular and neuroendocrine input into the kidney, glomerular filtration rate (GFR), and proteinuria as determinants of
the filtration function of the glomeruli, balance of electrolytes as an indicator of tubular function, podocyte number, foot process
effacement, mesangial deposition, glomerulosclerosis, and tubulointerstitial fibrosis on renal histology as indicators of disease severity, and
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response to internal and external stimuli. RTEC, renal tubular epithelial cell.
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Glomerular transcriptional profiles and protein–protein
interaction network in the glomerulus have been used to
identify molecular signatures responsible for these physiolog-
ical changes.91 Models of different tubular segments have
been developed to address absorption and secretion (re-
viewed by Weinstein92).
Structural models of various aspects of the renal anatomy
have been described. Because of advances in imaging
technologies, detailed three-dimensional reconstructions of
the nephron and surrounding blood vessels can be obtained
from serial sections.93,94 Nordsletten et al.95 reconstructed rat
renal vasculature from micro-computed tomography scans.
Other detailed three-dimensional glomerular reconstructions
have also been published.96,97 Recent studies have used
scanning electron microscopy with a high-sensitivity detector
to image the deepest regions of the filtration slits and
visualize the porous structure of the slit diaphragm.98 In the
future, it will be important to connect these morphological
characteristics to physiological functions and in turn to
cellular regulatory networks.
The application of systems biology approaches to under-
stand renal physiology is now termed as renal physiome.
Technological advances allow us to obtain quantitative
measurements of renal physiologic parameters and detailed
morphology. Development of detailed computational models
would help to integrate quantitative information of renal
physiology at different scales from renal cells to the whole
kidney. Independently, high-throughput genomics and pro-
teomics data sets, as described above, are being collected at
the tissue and cellular levels. Integrated models that merge
genomic and proteomic data with physiological data at the
cellular level are needed. Such models will have to successfully
merge the network analyses used to study the omics data sets
with differential equation-based dynamical analyses used for
physiological models. The development of simulation
environments, such as the Virtual Cell, makes this approach
feasible.99 Such models will serve as the base for building the
kidney physiome. The multiple levels of models that need to
be considered during the construction of an overall multi-
scale computational model of the functional kidney (i.e., the
kidney physiome) are summarized in Figure 3. A major
challenge in this field is how to integrate the multiscale data.
There is still a large gap between the functionality and the
true ability to use ontological data at the organ level to
inform molecular pathways. Furthermore, there is a lack of
strategies for integration of quantitative biological sources
stored in different standards.
SYSTEMS BIOMEDICINE OF KIDNEY DISEASES
Computational modeling of the multiple scales of disease
processes is at the core of systems biomedicine (Figure 4). To
capture the quantitative properties of diseases (i.e., severity,
manifestation of various signs and symptoms of the disease,
and rate of progression), investigators in the field of oncology
have linked clinical data from patients to molecular
signatures identified from malignant cells or tissues.100
High-quality data on clinical and pathological features and
specific molecular makers of diseases, which permitted the
linking of phenotype-to-genotypic variation in the study of
cancer biology, is still largely lacking in the field of
nephrology. One notable exception is the European Renal
cDNA Bank-Kro¨ner–Fresenius Biopsy Bank, which has
collected renal biopsy samples, as well as clinical and
histology reports. Data compiled by the European Renal
cDNA Bank-Kro¨ner–Fresenius Biopsy Bank have been used in
the study of several kidney diseases (reviewed in Neusser
et al.101). However, none of the published studies have fully
linked clinical data to molecular makers in a systems-wide
manner. Some studies have used one type of clinical data (for
example, histological diagnosis, severity of renal impairment,
rate of disease progression, extent of proteinuria, or specific
lab values) and correlated with data on gene expres-
sion.102–104 Although this is a necessary starting point, the
next step is to use a systems approach to profile the
relationship of multiple clinical data points with omic data
sets (for example, genome, transcriptome, or proteome) and
construct a genotype–phenotype interaction map as it had
been described for oncologic diseases.105,106 This relationship
between clinical characteristics and molecular features can
serve as bookend for the development of the kidney
physiome and increase our understanding of the regulatory
networks underlying the disease processes.
The major challenge in the field of systems medicine is the
imbalance between the large number of omic data sets and
the small sample size of patients with a well-defined disease
category. This causes significant issues for data analysis and
interpretation, leading to a so-called ‘multiple testing’
problem. To overcome this issue, it is critical to develop
national and international collaborative studies for collecting
large number of samples with strict disease classification
Clinical parameters Pathophysiology Molecular mechanisms
Phenome Physiome Omics
Molecular diagnosis Systems pharmacology
Systems biology
Personalized medicine
Molecular marker
sets to predict
disease progression
Figure 4 | Systems biomedicine of kidney diseases. The
capability to integrate clinical parameters, understand disease
pathophysiology, and discover molecular mechanisms of diseases
on the systems level will enable physicians to make more accurate
molecular diagnosis, to predict the prognosis of disease, and to
formulate targeted therapeutic agents. Together these
approaches will facilitate the individualization of patient care.
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criteria. An example of this approach is the Nephrotic
Syndrome Study Network, which is a major multicenter
initiative funded by the National Institutes of Health to enroll
patients with nephrotic syndrome (http://clinicaltrials.gov
NCT01209000). The aims of the project are to investigate the
underlying causes of the FSGS, minimal change disease, and
membranous nephropathy, identify effective treatment for
each disease, and develop meaningful approach to classify
these disorders in order to inform the selection of the most
effective treatments. Clinical data and biological samples
(kidney biopsy, urine, and blood) will be collected prospec-
tively. Transcriptomic profiles generated from the biological
samples will be used to identify transcriptional networks and
classify participants into distinct molecular subgroups. Such
an approach to prospectively enroll patients, gather biological
samples, and collect clinical data will be an invaluable
resource for future investigations as newer technologies
become available. With this we can expect to fill in the voids
in our molecular understandings of a group of clinical disease
categories that do not necessarily share the same molecular
underpinning.
In the current practice of renal medicine, nephrologists
formulate a clinical diagnosis, treatment plan, or prediction
on disease progression using a rather restricted set of clinical
parameters. These clinical findings are direct and indirect
reflections of the underlying molecular and cellular processes.
Different diseases often share similar clinical manifestation
and cannot be distinguished from each other using the
currently available knowledge and tools. To better character-
ize disease processes, software systems that are capable of
handling the analysis of multivariant data and predict disease
classification by machine-learning approaches have been
developed. The goal is to achieve further characterization and
classification of disease processes using currently available
clinical and molecular data sets as biological classifiers.
Instead of sorting patients into broad clinical categories, such
as responder versus non-responder to a particular treatment,
the systems biomedicine approach is to refine the categoriza-
tion of diseases and be able to distinguish the genetic and
phenotypic individuality of any given patient and tailor a
specific therapeutic plan. Systems level analysis may identify a
particular set of single-nucleotide polymorphism variants,
transcriptomic profile, and urine proteomic and metabolo-
mic characteristics that could be translated into clinical tests
to help identify patients who are more or less likely to
respond to a particular treatment or have a faster or slower
progression of renal function loss leading to more person-
alized medicine.
Another major challenge in the field of chronic kidney
disease is the lack of the early hard outcomes for clinical
studies because disease progression usually takes decades.
Biomarkers derived from omics studies could help predict the
response of drugs at an early stage without waiting for the
development of ‘hard outcomes’ such as doubling of
creatinine or progression to end-stage renal disease, which
might take years. Validation of omics biomarkers as early
predictors of disease in prospective studies is required but
hard to achieve, given the relatively low incidence of
glomerular diseases, with the exception of DN. Therefore,
the national and international collaborative studies are
needed to study these diseases with low incidence.
DRUG DISCOVERY USING SYSTEMS PHARMACOLOGY
Treatment options for kidney disease are currently quite
limited. Most primary glomerular diseases are still treated
with steroids and immunosuppressive medications. Long-
term use of these medications can cause significant side
effects, including severe infections and malignancies. At-
tempts have been made to develop more specific drugs to
treat diabetic kidney disease. Although multiple phase II
clinical trials had shown promising results, the only
successful examples are studies using angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers,107–111
whereas many trials including aminoguanidine112,113 and
sulodexide (http://clinicaltrials.gov identifier NCT00130208)
failed in phase III clinical trials. A large body of evidence
suggests that transforming growth factor-b has a key role in
kidney fibrosis. Many drug companies have tried to develop
anti-transforming growth factor-b agents in the last decade.
However, they are limited to phase II studies. It is generally
believed that podocyte injury is an early event leading to
glomerular disease. Therefore, several groups have tried to
develop specific drugs to prevent podocyte injury. We have
recently found that retinoic acid can protect podocytes from
injury in an animal model of human immunodeficiency
virus-associated nephropathy.114 However, these approaches
are still limited to experimental models of disease. Overall,
traditional approaches to discover drugs to treat kidney
disease have not been largely successful. This lack of success
indicates that a different approach is needed.
Systems pharmacology is an alternative approach to
discover drugs to treat complex diseases such as kidney
diseases. Systems pharmacology views therapeutic targets of
drugs as parts of cellular networks that control physiological
responses.115 This approach is useful in understanding drug
action both therapeutic and adverse. We have used this
approach to study cardiac arrhythmia.115 Network analyses of
arrhythmias suggest that the genes involved in arrhythmias
form an identifiable region (subnetwork) within the human
interactome. Identifying such disease-specific subnetworks
within the human interactome and determining whether key
components within these subnetworks are expressed in the
tissue of interest are potential approaches to identify new
drug targets and disease-specific genes. Omics studies that are
used to develop biomarker sets for disease progression can
also be used to identify disease-specific subnetworks within
the human interactome, which can serve as the basis for
identifying new drug targets. In addition, such subnetworks
can also be used to repurpose current drugs for the treatment
of kidney diseases if their therapeutic targets fall within the
disease-specific subnetworks. Such potential drug targets
could then be computationally validated using dynamical
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models to determine whether drug-dependent change in
activity of the target will affect overall physiological function.
This type of computational prescreening could help reduce
the cost of developing new drugs for kidney diseases and
predict adverse events in susceptible populations.
CONCLUSIONS AND PERSPECTIVE
It is increasingly clear that diseases, such as most kidney
diseases, with complex pathophysiologies will require that we
understand the physiology at the level of molecular and
cellular networks at the genome-wide scale, both to predict
disease progression and to develop drugs for treatment.
Systems biology approaches can be used to develop an
understanding of how alterations in cellular components and
interactions lead to pathophysiology. Integrated analyses of
omics profiles derived from the genome, transcriptome,
proteome, and metabolome levels is the first step in realizing
a systems view of cellular processes. However, merging these
different experimental data sets, for example, mRNA
concentration and protein abundance profiles, is not
straightforward, as a direct overlap of differentially regu-
lated/abundant features, resulting from transcriptomics and
proteomics, is often limited. Furthermore, it is important to
consider the regulatory mechanisms of transcription by
post-translational modifications and protein degradation,
and epigenetic regulation. Some studies suggest that the
analysis of transcriptomic and proteomic data on the level of
protein interaction networks may be a way of identifying the
link between the two data sets.116 Changes in metabolite
levels do not necessarily parallel changes in the transcriptome
or the proteome because changes in the level of a particular
transcript do not necessarily result in an instantaneous
change in enzymatic activity. Therefore, it is essential to
investigate the changes in gene transcripts, proteins, and
metabolites of the same individual over multiple time points
in order to understand their regulatory relationship at a
systems level. Although this is a challenge that needs to be
addressed within the context of basic systems biology, such
integration is critical for the development of systems
biomedicine as a clinically useful discipline.
A major challenge in unraveling the complexity of disease
mechanisms is to integrate GWA studies with gene expression
patterns in order to establish the mechanistic connections
between the measured genotype and observed phenotype.
For renal disease, the availability of both tissue- and disease-
specific expression data sets makes such a strategy feasible.
Computational approaches in systems biology such as
network analysis will have a major role in developing this
genotype-to-phenotype connection. Connecting experimen-
tal data at different scales from genes to cellular networks to
organ function will help to identify molecular signatures for
renal physiology and physiopathology. Integration of omic
data sets obtained over extended time periods during the
progression of kidney diseases could provide the mechanistic
understanding of how multiple factors coordinately regulate
the induction and progression of kidney diseases. Integration
of these dynamic changes at molecular levels with clinical
parameters will be the key step in the process of identifying
the biological basis and developing biomarkers and ther-
apeutic agents of kidney diseases.
When comparing large data sets with millions of data
points, the likelihood of detecting a false positive is high. One
of the major challenges is to identity and sort out changes on
the molecular and physiological levels that actually have an
impact on the clinical outcome of the individual. Qualitative
and strict statistical interpretation of findings needs to be
applied first in order to avoid spurious findings and
interpretations.
There is no doubt that there is considerable work that
needs to be done at both the experimental and computational
levels to successfully apply systems biology to treat kidney
diseases. Challenges range all the way from developing
appropriate standard techniques to obtain patient samples to
the development of complex multiscale models that explicitly
integrate genomic information with clinical data. In spite of
these challenges, the systems biology approaches described
here provide a clearly identifiable path by which our
knowledge of biological mechanisms can be used to better
diagnose and treat kidney diseases (Figure 4).
The focus of future systems biology studies in kidney
disease is to identify reliable early biomarkers for molecular
diagnosis and prediction of disease progression. The
discovery of the reliable biomarkers requires massive efforts
from nephrologists to collect a large number of samples from
patients with well-defined disease category. To achieve this,
we need to develop international collaboration among the
physicians, epidemiologists, molecular biologists, statisti-
cians, and systems biologists with computer science and
mathematical backgrounds. The discovery of new biomarkers
will improve the design of clinical trials and identify patients
at an earlier stage of the disease. Integrating the large omic
data sets with drug and disease databases could guide the
prediction of drug efficacy and side effects. These systems
approaches could eventually help us reduce the chance of fails
when we move clinical trials of new drugs from phase II to
phase III. Advancements in this field will eventually lead to
personalized medicine to treat patients with different
subtypes of kidney diseases at different stages of progression.
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